Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors

Genes and Development

Volumn 12, Issue 8, 1998, Pages 1121-1133

  McClatchey, Andrea I ^a,d   Saotome, Ichiko ^a   Mercer, Kim ^a   Crowley, Denise ^a   Gusella, James F ^c   Bronson, Roderick T ^b   Jacks, Tyler ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytoskeleton; Merlin; Metastasis; NF2; Osteosarcoma; Tumor suppressor

Indexed keywords

ANIMAL MODEL; ARTICLE; CANCER GENETICS; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY; HETEROZYGOSITY LOSS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALIA; FALCO COLUMBARIUS;

EID: 0032522603     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.12.8.1121     Document Type: Article

References (51)

1. Bronson, R.T. 1990. Rate of occurrence of lesions in 20 inbred and hybrid genotypes of rats and mice sacrificed at 6 month intervals during the first years of life. In Genetic effects on aging II (ed. D.E. Harrison), pp. 279-357. The Telford Press, Inc., Caldwell, NJ.
2. Chambers, A.F., I.C. MacDonald, E.E. Schmrdt, S. Koop, V.L. Morris, R. Khokha, and A.C. Groom. 1995. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev. 14: 279-301.
3. Claudio, J.O., R.W. Veneziale, A.S. Menko, and G.A. Rouleau. 1997. Expression of schwannomin in lens and Schwann cells. Neuroreport 8: 2025-2030.
4. Crepaldi, T., A. Gautreau, P.M. Comoglio, D. Louvard, and M. Arpin. 1997. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J. Cell Biol. 138: 423-434.
5. Dietrich, W.F., J. Miller, R. Steen, M.A. Merchant, D. Damron-Boles, Z. Husain, R. Dredge, M.J. Daly, K.A. Ingalls, T.J. O'Connor, C.A. Evans, M.M. DeAngelis, D.M. Levinson, L. Kruglyak, N. Goodman, N.G. Copeland, N.A. Jenkins, T.L. Hawkins, L. Stein, D.C. Page, and E.S. Lander. 1996. A comprehensive genetic map of the mouse genome (see comments) [published erratum appears in Nature (1996) 381: 172]. Nature 380: 149-152.
6. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
7. Finkel, M.P., B.O. Biskis, and P.B. Jinkins. 1966. Virus induction of osteosarcomas in mice. Science 151: 698-701.
8. Frisch, S.M. and E. Ruoslahti. 1997. Integrins and anoikis. Curr. Opin. Cell Biol 9: 701-706.
9. Frith, C.H. and J.M. Ward. 1979. A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J. Environ. Pathol. Toxicol. 3: 329-351.
10. Frith, C.H., N.A. Littlefield, and R. Umholtz. 1981. Incidence of pulmonary metastases for various neoplasms in BALB/cStCrlfC3H/Nctr female fed N-2-fluorenylacetamide. J. Natl. Cancer Inst. 66: 703-712.
11. Gary, R. and A. Bretscher. 1993. Heterotypic and homotypic associations between ezrin and moesin, two putative membrane-cytoskeletal linking proteins. Proc. Natl. Acad. Sci. 90: 10846-10850.
12. Gonzalez-Agosti, C., L. Xu, D. Pinney, R. Beauchamp, W. Hobbs, J.F. Gusella, and V. Ramesh. 1996. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 13: 1239-1247.
13. Gusella, J.F., V. Ramesh, M. MacCollin, and L.B. Jacoby. 1996. Neurofibromatosis 2: Loss of merlin's protective spell. Curr. Opin. Genet. Dev. 6: 87-92.
14. Haase, V.H., J.A. Trofatter, M. MacCollin, E. Tarttelin, J.F. Gusella, and V. Ramesh. 1994. The murine NF2 homolog ue encodes a highly conserved merlin protein with alternative forms. Hum. Mol. Genet. 3: 407-411.
15. Habets, G.G., E.H. Scholtes, D. Zuydgeest, R.A. van der Kammen, J.C. Stam, A, Berns, and J.G. Collard. 1994. Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell 77: 537-549.
16. Helander, T.S., O. Carpen, O. Turunen, P.E. Kovanen, A. Vaheri, and T. Timonen. 1996. ICAM-2 redistributed by ezrin as a target for killer cells. Nature 382: 265-268.
17. Hirao, M., N. Sato, T. Kondo, S. Yonemura, M. Monden, T. Sasaki, Y. Takai, S. Tsukita, and S. Tsukita. 1996. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: Possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J. Cell Biol 135: 37-51.
18. Hurford, R.K. Jr., D. Cobrinik, M.H. Lee, and N. Dyson. 1997. pRB and p 107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes & Dev. 11: 1447-1463.
19. Huson, S.M. 1994. Neurofibromatosis 2: Clinical features, genetic counseling and management issues. In The neurofibromatoses: A practical and clinical overview (ed. S.M. Huson and R.A.C. Hughes), pp. 211-233. Chapman and Hall Medical Press, London, UK.
20. Huynh, D.P. and S.M. Pulst. 1996. Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells. Oncogene 13: 73-84.
21. Jacks, T., L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, and R.A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-7.
22. Kaul, S.C., Y. Mitsui, Y. Komatsu, R.R. Reddel, and R. Wadhwa. 1996. A highly expressed 81 kDa protein in immortalized mouse fibroblasts: its proliferative function and identity with ezrin. Oncogene 13: 1231-1237.
23. Kincade, P.W., Z. Zheng, S. Katoh, and L. Hanson. 1997. The importance of cellular environment to function of the CD44 matrix receptor. Curr. Opin. Cell Biol. 9: 635-642.
24. Knowles, B.B., J. McCarrick, N. Fox, D. Solter, and I. Damjanov. 1990. Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T- antigen hybrid gene. Am. J. Pathol. 137: 259-262.
25. Lamb, R.F., R.F. Hennigan, K. Turnbull, K.D. Katsanakis, E.D. MacKenzie, G.D. Birnie, and B.W. Ozanne. 1997a. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol. Cell Biol. 17: 963-976.
26. Lamb, R.F., B.W. Ozanne, C. Roy, L. McGarry, C. Stipp, P. Mangeat, and D.G. Jay. 1997b. Essential functions of ezrin in maintenance of cell shape and lamellipodial extension in normal and transformed fibroblasts. Curr. Biol. 7: 682-688.
27. Lee, M.H., B.O. Williams, G. Mulligan, S. Mukai, R.T. Bronson, N. Dyson, E. Harlow, and T. Jacks. 1996. Targeted disruption of p107: Functional overlap between p107 and Rb. Genes & Dev. 10: 1621-1632.
28. Luongo, C., A.R. Moser, S. Gledhill, and W.F. Dove. 1994. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res. 54: 5947-5952.
29. Lutchman, M. and G.A. Rouleau. 1995. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res. 55: 2270-2274.
30. Luz, A., W. Gossner, and A.B. Murray. 1991. Osteosarcoma, spontaneous and radiation-induced, mouse. In Cardiovascular and musculoskeletal systems (ed. T.C. Jones, U. Mohr, and R.D. Hunt), pp. 202-213. Springer-Verlag, Berlin, Germany.
31. Mackay, D.J., F. Esch, H. Furthmayr, and A. Hall. 1997. Rho-and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. J. Cell Biol. 138: 927-938.
32. Matsui, T., M. Maeda, Y. Doi, S. Yonemura, M. Amano, K. Kaibuchi, S. Tsukita, and S. Tsukita. 1998. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell Biol. 140: 647-657.
33. McCartney, B.M. and R.G. Fehon. 1996. Distinct cellular and suhcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin. J. Cell Biol. 133: 843-852.
34. McClatchey, A.I., I. Saotome, V. Ramesh, J.F. Gusella, and T. Jacks. 1997. The The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes & Dev. 11: 1253-1265.
35. Michiels, L. and J. Merregaert. 1993. Retroviruses and oncogenes associated with osteosarcomas. Cancer Treat. Res. 62: 7-18.
36. Rizzoli, R. and J.P. Bonjour. 1997. Hormones and bones. Lancet (Suppl. 1) 349: SI20-23.
37. Rouleau, G.A., P. Merel, M. Lutchman, M. Sanson, J. Zucman, C. Marineau, K. Hoang-Xuan, S. Demczuk, C. Desmaze, B. Plougastel, S.M. Pulst, G. Lenoir, E. Bijlsma, R. Fashold, J. Dumanski, P. de Jong, D. Parry, R. Eldridge, A. Aurias, O. Delatttre, and G. Thomas. 1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363: 515-521.
38. Ruther, U., D. Komitowski, F.R. Schubert, and E.F. Wagner. 1989. c-fos expression induces bone tumors in transgenic mice. Oncogene 4: 861-865.
39. Sainio, M., F. Zhao, L. Heiska, O. Turunen, M. Bakker, E. Zwarthoff, M. Lutchman, G.A. Rouleau, J. Jaaskelainen, A. Vaheri, and O. Carpen. 1997. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J. Cell Sci. 110: 2249-2260.
40. Shaw, R.J., A.I. McClatchey, and T. Jacks. 1998. Regulation of the neurofibromatosis type 2 tumor suppressor protein, marlin, by adhesion and growth arrest stimuli. J. Biol. Chem. (in press).
41. Simpson, E.M., C.C. Linder, E.E. Sargent, M.T. Davisson, L.E. Mobraaten, and J.J. Sharp. 1997. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nature Genet. 16: 19-27.
42. Takahashi, K., T. Sasaki, A. Mammoto, K. Takaishi, T. Kameyama, S. Tsukita, and Y. Takai. 1997. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J. Biol. Chem. 272: 23371-23375.
43. Takeshima, H., I. Izawa, P.S. Lee, N. Safdar, V.A. Levin, and H. Saya. 1994. Detection of cellular proteins that interact with the NF2 tumor suppressor gene product. Oncogene 9: 2135-2144.
44. Taverna, D., M. Ullman-Cullerè, H. Rayburn, R.T. Bronson, and R.O. Hynes. 1998. A test for the role of alpha 5 integrin/fibronectin interactions in tumorigenesis. Cancer Res. 58: 848-853.
45. Trofatter, J.A., M.M. MacCollin, J.L. Rutter, J.R. Murrell, M.P. Duyao, D.M. Parry, R. Eldridge, N. Kley, A.G. Menon, K. Pulaski, V.H. Haase, C.M. Ambrose, D. Munroe, C. Bove, J.L. Haines, R.L. Martuza, M.E. MacDonald, B.R. Seizinger, M.P. Short, A.J. Buckler, and J.F. Gusella. 1993. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor [published erratum appears in Cell (1993) 75: 826]. Cell 72: 791-800.
46. Tsukita, S., K. Oishi, N. Sato, J. Sagara, A. Kawai, and S. Tsukita. 1994. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J. Cell Biol. 126:391-401.
47. Tsukita, S., S. Yonemura, and S. Tsukita. 1997. ERM proteins: Head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem. Sci 22: 53-58.
48. Vaheri, A., O. Carpen, L. Heiska, T.S. Helander, J. Jaaskelainen, P. Majander-Nordenswan, M. Sainio, T. Timonen, and O. Turunen. 1997. The ezrin protein family: membrane-cytoskeleton interactions and disease assoeiations. Curr. Opin. Cell Biol. 9: 659-666.
49. Van Aelst, L. and C. D'Souza-Schorey. 1997. Rho GTPases and signaling networks. Genes & Dev. 11: 2295-2322.
50. Vesselinovitch, S.D., N. Mihailovich, and K.V. Rao. 1978. Morphology and metastatic nature of induced hepatic nodular lesions in C57BL × C3H F1 mice. Cancer Res. 38: 2003-2010.
51. Wilkie, T.M., R.A. Schmidt, M. Baetscher, and A. Messing. 1994. Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen. Oncogene 9: 2889-2895.